compounding glp-1 enforcement news FDA Crackdown on Compounded Drugs Compounded GLP-1 FAQ - American

June 2, 2026 Update: New research has raised concerns that GLP-1 receptor agonist medications like Ozempic, Wegovy and Mounjaro may be associated with a significantly increased risk of non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition that can cause sudden and permanent vision loss

Drug manufacturers are focusing on developing more oral GLP-1 receptor agonists to meet patients' needs

Additionally, various herbal products from Southeast Asiasuch as rosemaryhave shown neuroprotective properties by preventing encephalitis and suppressing A accumulation

Cell 65, 824

Patients should be aware that: No licensed combination product exists in the UK Any combination use would be considered experimental and is not supported by current evidence Clinical decisions must be guided by a qualified healthcare professional with access to current trial data Clinical Evidence and Trial Data Available to UK Patients Retatrutide Phase 2 data showed approximately 24% mean body weight reduction at the highest dose over 48 weeks, but no published trial data exist for the specific cagrilintideretatrutide combination

Combination of PARPi and anti-PD-L1 therapies in ovarian cancer